Drug Trial Radar · NCT06978725
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Apr 9, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Priovant Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Conditions
- Cutaneous Sarcoidosis
Interventions
Oral BrepocitinibDrug
Oral Brepocitinib
Oral PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0Time frame: Week 16
- Part 2: Proportion of participants achieving a reduction in Cutaneous Sarcoidosis Activity and Morphology Instrument Activity (CSAMI-A) from baseline to Week 16.Time frame: 16 Weeks
Locations
44 sites in 3 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Birmingham, Alabama · Recruiting
Clinical Trial Site
Phoenix, Arizona · Recruiting
Clinical Trial Site
Tucson, Arizona · Recruiting
Clinical Trial Site
San Francisco, California · Recruiting
Clinical Trial Site
New Haven, Connecticut · Recruiting
Clinical Trial Site
Washington D.C., District of Columbia · Recruiting
Clinical Trial Site
Atlanta, Georgia · Recruiting
Clinical Trial Site
Sandy Springs, Georgia · Recruiting
Clinical Trial Site
Chicago, Illinois · Recruiting
Clinical Trial Site
Chicago, Illinois · Recruiting
Clinical Trial Site
Kansas City, Kansas · Recruiting
Clinical Trial Site
Louisville, Kentucky · Recruiting
Clinical Trial Site
New Orleans, Louisiana · Recruiting
Clinical Trial Site
Baltimore, Maryland · Recruiting
Clinical Trial Site
Boston, Massachusetts · Recruiting
Clinical Trial Site
Ann Arbor, Michigan · Recruiting
Clinical Trial Site
Ann Arbor, Michigan · Recruiting
Clinical Trial Site
Troy, Michigan · Recruiting
Clinical Trial Site
St Louis, Missouri · Recruiting
Clinical Trial Site
Lebanon, New Hampshire · Recruiting
Clinical Trial Site
Brooklyn, New York · Recruiting
Clinical Trial Site
Lake Success, New York · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
Rochester, New York · Recruiting
Clinical Trial Site
Chapel Hill, North Carolina · Recruiting
Clinical Trial Site
Durham, North Carolina · Recruiting
Clinical Trial Site
Greenville, North Carolina · Recruiting
Clinical Trial Site
Cleveland, Ohio · Recruiting
Clinical Trial Site
Fairborn, Ohio · Recruiting
Clinical Trial Site
Hershey, Pennsylvania · Recruiting
Clinical Trial Site
Philadelphia, Pennsylvania · Recruiting
Clinical Trial Site
Philadelphia, Pennsylvania · Recruiting
Clinical Trial Site
Charleston, South Carolina · Recruiting
Clinical Trial Site
Houston, Texas · Recruiting
Clinical Trial Site
Norfolk, Virginia · Recruiting
Clinical Trial Site
Richmond, Virginia · Recruiting
Clinical Trial Site
Madison, Wisconsin · Recruiting
Clinical Trial Site
Milwaukee, Wisconsin · Recruiting
Clinical Trial Site
Melbourne, Victoria, Australia · Recruiting
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.